Xencor, Inc Finite-Lived Intangible Asset, Expected Amortization, Year Three
Xencor, Inc (XNCR) had Finite-Lived Intangible Asset, Expected Amortization, Year Three of $328.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree · last filed 2026-08-05
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year Three $328.00K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $342.00K.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $585.00K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year Three $577.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Three |
|---|---|
| 2026-06-30 | $328.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $342.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $585.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | $577.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $576.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $699.00K 10-Q · filed 2025-05-07 |
| 2024-12-31 | $985.00K 10-K · filed 2025-02-27 |
| 2023-12-31 | $961.00K 10-K/A · filed 2025-02-24 |
| 2022-12-31 | $1.11M 10-K · filed 2023-02-27 |
| 2021-12-31 | $770.00K 10-K · filed 2022-02-24 |
| 2020-12-31 | $829.00K 10-K · filed 2021-02-24 |
| 2019-12-31 | $880.00K 10-K · filed 2020-02-25 |
| 2018-12-31 | $757.00K 10-K · filed 2019-02-26 |
| 2017-12-31 | $780.00K 10-K · filed 2018-02-28 |
| 2016-12-31 | $682.00K 10-K · filed 2017-03-01 |
| 2015-12-31 | $628.00K 10-K · filed 2016-03-08 |
| 2014-12-31 | $538.00K 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |